Unilife Corporation (UNIS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.75+0.02 (+1.16%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close1.73
Bid0.00 x
Ask2.28 x 200
Day's Range1.65 - 1.84
52wk Range1.58 - 12.90
1y Target EstN/A
Market Cap29.5M
P/E Ratio (ttm)-0.32
Avg Vol (3m)103,543
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire24 days ago

    Unilife Corporation Provides Trading Update

    YORK, Pa., Sept. 29, 2016 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS; ASX: UNS) announced today that the Company will not be able to file its audited ...

  • PR Newswirelast month

    Unilife Corporation Announces Receipt of Delinquency Letter from NASDAQ Relating to Fiscal 2016 Form 10-K

    ASX: UNS) announced today that it has received a letter (the "NASDAQ letter") from The NASDAQ Stock Market LLC ("NASDAQ") notifying the Company that it is not in compliance with NASDAQ Listing Rule 5250(c)(1) because it has not filed its Annual Report on Form 10-K for the period ended June 30, 2016 (the "Form 10-K") in a timely manner with the Securities and Exchange Commission (the "SEC").  NASDAQ Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the SEC. As previously disclosed, the Company has not timely filed its Quarterly Report on Form 10-Q for the period ended March 31, 2016.  As a result, the Company submitted a plan (the "Original Compliance Plan") to NASDAQ as to how it plans to regain compliance with NASDAQ's continued listing requirements.  NASDAQ subsequently granted the Company an exception until November 7, 2016 (the "Filing Deadline") to regain compliance with NASDAQ Listing Rule 5250(c)(1).

  • PR Newswire3 months ago

    Unilife Announces New Leadership Team and Targeted Growth Strategy

    ASX: UNS) today announced new management and Board appointments, a strategic focus on wearable injectors, and an update to its internal investigation. John Ryan, who has served as Interim Chief Executive Officer since March 2016 and Senior Vice President, General Counsel and Secretary since 2014, has been named President and Chief Executive Officer and appointed to the Board of Directors. Michael E. Kamarck, Ph.D., former President of Merck BioVentures, has also joined the Company's Board of Directors.